PULS Cardiac Test enhances risk assessment by evaluating clinical risk factors as well as 7 unique protein biomarkers associated with atherosclerotic disease progression and plaque vulnerability. PULS has demonstrated accuracy in predicting risk for cardiac events and was validated in the Multi-Ethnic Study of Atherosclerosis
TMAO (trimethylamine N-oxide) which has been shown to regulate various physiological processes involved in the development of atherosclerosis
ADMA and SDMA measures an individual with multiple risk factors for the development of cardiovascular disease. Eleveated ADMA levels are associated with significant subclinical atherosclerosis. When elevated SDMA levels associated with impaired kidney function and strongly correlate with reduced eGFR.
Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk.
Lp-PLA2 is an independent predictor of incident coronary heart disease A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
Urinary Microalbumin is a biomarker in renal and cardiovascular disease
High-sensitivity C-reactive Protein used in the prediction of first cardiovascular events.Indicates an inflammatory process is going on.
Oxidized LDL Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events.
F2-Isoprostanes an indicator and risk factor for coronary heart disease. Systematic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. F2a as a risk marker in patients with coronary heart disease.
Advanced Lipid measures for prediction of coronary heart disease in men and women
ApolipoproteinB (ApoB), Apolipoprotein A (ApoA1), ApoB/ApoA1 Ratio, Small Dense LDL (sdLDL), Lipoprotein(a) [Lp(a)], HDL2b
Other Advanced Cardiovascular and Metabolic Tests:
Coenzyme Q10, Adiponectin, Galectin-3, AspirinWorks, NT-proBNP